Since the the Food and Drug Administration (FDA) approved brexanolone as an intravenous infusion for the treatment of postpartum depression last week, we have been deluged with questions from patents, providers and the media regarding [...]
The excitement over the FDA approval of brexanolone (to be marketed as Zulresso) is a good place to start this week’s roundup.  Brexanolone is a derivative of the neurosteroid allopregnanolone, and, while Zulpresso was approved [...]
Several weeks ago, the US Preventive Services Task Force (USPSTF) issued recommendations that all pregnant and postpartum women should be evaluated in order to determine risk for depressive illness and suggests that women at increased [...]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD). Â SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors. Â Since that time, Sage Therapeutics [...]
This week another study highlights the importance of prenatal vitamins in reducing the risk of autism spectrum disorders (ASD). Â This study from Schmidt and colleagues focused on high-risk families. In these families, one child had [...]
Postpartum depression (PPD) is a common and complicated illness, affecting about 15% of women in the perinatal period. Recent research from the PACT consortium (Postpartum Depression: Action Toward Causes and Treatment) has sought to classify [...]
This week there are a series of articles related to the recommendations issued by the US Preventive Services Task Force (USPSTF) several weeks ago, stating that all pregnant and postpartum women should be evaluated in [...]
Women with postpartum depression often complain of social isolation, and multiple studies have documented that having inadequate social supports is a risk factor for postpartum depression.  A recent study suggests that increasing a mother’s social [...]
In 2016, the US Preventive Services Task Force (USPSTF) recommended that all adults, including pregnant and postpartum women, should be screened for depression; the task force has extended those recommendations by stating that all pregnant [...]
According to a recent analysis of national data by the Centers for Disease Control, the number of pregnant women with opioid use disorder (as documented at the time of delivery) more than quadrupled from 1999 [...]
